BUSINESS SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Business Segment Information [Text Block]

BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets and planning and forecasting future periods.

Product revenues and the composition of total revenues were as follows:

	Three Months Ended March 31,
Dollars in Millions	2017		2016
Prioritized Brands
Opdivo	$	1,127	$	704
Eliquis	1,101		734
Orencia	535		475
Sprycel	463		407
Yervoy	330		263
Empliciti	53		28
Established Brands
Hepatitis C Franchise	162		427
Baraclude	282		291
Sustiva Franchise	184		273
Reyataz Franchise	193		221
Other Brands	499		568
Total Revenues	$	4,929	$	4,391
Net product sales	$	4,580	$	3,964
Alliance revenues	297		409
Other revenues	52		18
Total Revenues	$	4,929	$	4,391